XADAGO
Peaksafinamide mesylate
NDAORALTABLET
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 2h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XADAGO (safinamide mesylate) is an oral monoamine oxidase type B inhibitor approved in 2017 for Parkinson's disease. It is used as an adjunctive therapy to levodopa/carbidopa in patients experiencing motor fluctuations. The drug works by inhibiting MAO-B, increasing dopamine availability in the brain.
$0.003BPart D
Peak4.4 years to LOEProduct is at peak lifecycle with modest Part D spending ($3M, 1,377 claims in 2023), suggesting a stable but niche market presence with moderate commercial team support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
Started Nov 2017
164 enrolled
Idiopathic Parkinson Disease
Why This Matters for Your Career
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.